These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 3545931)
1. Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up. Quatraro A; Consoli G; Ceriello A; Giugliano D Diabete Metab; 1986 Dec; 12(6):315-8. PubMed ID: 3545931 [TBL] [Abstract][Full Text] [Related]
2. Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure. Chazan AC; Gomes MB Braz J Med Biol Res; 2001 Jan; 34(1):49-56. PubMed ID: 11151028 [TBL] [Abstract][Full Text] [Related]
3. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Pugh JA; Wagner ML; Sawyer J; Ramirez G; Tuley M; Friedberg SJ Diabetes Care; 1992 Aug; 15(8):953-9. PubMed ID: 1387073 [TBL] [Abstract][Full Text] [Related]
4. Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure. Ravnik-Oblak M; Mrevlje F Diabetes Res Clin Pract; 1995 Oct; 30(1):27-35. PubMed ID: 8745203 [TBL] [Abstract][Full Text] [Related]
5. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes. Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038 [TBL] [Abstract][Full Text] [Related]
6. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524 [TBL] [Abstract][Full Text] [Related]
7. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Chow CC; Tsang LW; Sorensen JP; Cockram CS Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472 [TBL] [Abstract][Full Text] [Related]
8. Gliclazide on long-term therapy increases insulin response to glucose of type II diabetics. Couturier E Diabetes Res Clin Pract; 1985-1986 Mar; 1(6):343-7. PubMed ID: 3915271 [TBL] [Abstract][Full Text] [Related]
9. Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent. Osei K; Falko JM Am J Med Sci; 1985 Apr; 289(4):148-53. PubMed ID: 3920907 [TBL] [Abstract][Full Text] [Related]
10. Effect of prolonged gliclazide therapy in non-insulin dependent diabetic subjects. Donatelli M; Sinagra D; Russo V; Bucalo ML; Giardina E; Cerasola GA; Bompiani G Pharmatherapeutica; 1985; 4(2):69-75. PubMed ID: 3903780 [TBL] [Abstract][Full Text] [Related]
11. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Satoh J; Takahashi K; Takizawa Y; Ishihara H; Hirai M; Katagiri H; Hinokio Y; Suzuki S; Tsuji I; Oka Y Diabetes Res Clin Pract; 2005 Dec; 70(3):291-7. PubMed ID: 15949862 [TBL] [Abstract][Full Text] [Related]
12. Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes. Chandra ST; Priya G; Khurana ML; Jyotsna VP; Sreenivas V; Dwivedi S; Ammini AC Diabetes Technol Ther; 2008 Oct; 10(5):363-8. PubMed ID: 18715212 [TBL] [Abstract][Full Text] [Related]
13. Factors for development of secondary failure to sulfonylurea drugs in non-insulin-dependent diabetes mellitus. Borissova AM; Koev DG; Minev MG; Martinova FG; Gencova PI; Kirilov GG; Arnaudov J Acta Diabetol Lat; 1991; 28(1):91-8. PubMed ID: 1862695 [TBL] [Abstract][Full Text] [Related]
14. Home blood glucose monitoring in non-insulin-dependent diabetics: the effect of gliclazide on blood glucose and weight control, a multicentre trial. Shaw KM; Wheeley MS; Campbell DB; Ward JD Diabet Med; 1985 Nov; 2(6):484-90. PubMed ID: 2951123 [TBL] [Abstract][Full Text] [Related]
15. Combined insulin and sulfonylurea therapy for type 2 diabetes mellitus. Riddle MC Diabetes Res Clin Pract; 1991 Jan; 11(1):3-8. PubMed ID: 2019232 [No Abstract] [Full Text] [Related]
16. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. Harrower AD J Diabetes Complications; 1994; 8(4):201-3. PubMed ID: 7833494 [TBL] [Abstract][Full Text] [Related]
17. Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes. Roden M; Mariz S; Brazzale AR; Pacini G J Intern Med; 2009 Apr; 265(4):476-87. PubMed ID: 19298459 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Johnson JL; Wolf SL; Kabadi UM Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835 [TBL] [Abstract][Full Text] [Related]
19. Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics. Brogard JM; Pinget M; Dorner M Curr Med Res Opin; 1984; 9(1):56-63. PubMed ID: 6373160 [TBL] [Abstract][Full Text] [Related]
20. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. Güvener N; Gedik O Acta Diabetol; 1999 Jun; 36(1-2):93-7. PubMed ID: 10436259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]